Cargando…
Pharmacokinetics of the Rac/Cdc42 Inhibitor MBQ-167 in Mice by Supercritical Fluid Chromatography–Tandem Mass Spectrometry
[Image: see text] The Rho GTPases Rac and Cdc42 are potential targets against metastatic diseases. We characterized the small molecule MBQ-167 as an effective dual Rac/Cdc42 inhibitor that reduces HER2-type tumor growth and metastasis in mice by ∼90%. This study reports the pharmacokinetics and tiss...
Autores principales: | Maldonado, María del Mar, Rosado-González, Gabriela, Bloom, Joseph, Duconge, Jorge, Ruiz-Calderón, Jean F., Hernández-O’Farrill, Eliud, Vlaar, Cornelis, Rodríguez-Orengo, José F., Dharmawardhane, Suranganie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2019
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6843717/ https://www.ncbi.nlm.nih.gov/pubmed/31720502 http://dx.doi.org/10.1021/acsomega.9b01641 |
Ejemplares similares
-
Characterization of Novel Derivatives of MBQ-167, an Inhibitor of the GTP-binding Proteins Rac/Cdc42
por: Medina, Julia I., et al.
Publicado: (2022) -
Physiologically-Based Pharmacokinetic/Pharmacodynamic Model of MBQ-167 to Predict Tumor Growth Inhibition in Mice
por: Reig-López, Javier, et al.
Publicado: (2020) -
Targeting Rac and Cdc42 GEFs in Metastatic Cancer
por: Maldonado, Maria del Mar, et al.
Publicado: (2020) -
Rac and Cdc42 inhibitors reduce macrophage function in breast cancer preclinical models
por: Torres-Sanchez, Anamaris, et al.
Publicado: (2023) -
The Rac inhibitor HV-107 as a potential therapeutic for metastatic breast cancer
por: Crespo, Grace Velez, et al.
Publicado: (2023)